Business Wire

Janssen to present growing set of oncology data at the 2016 European Society for Medical Oncology (ESMO) Congress

Del

Janssen-Cilag International NV today announced data from ten company-sponsored abstracts will be presented at the 2016 ESMO Congress in Copenhagen, Denmark, on the 9th and 10th October 2016. The data feature four Janssen medicines spanning multiple disease areas including prostate, urothelial and blood cancer, and showcase Janssen’s broad portfolio in oncology and commitment to patients.

“The data to be presented at ESMO highlights the efficacy and safety profiles of Janssen treatments and also provides insights from a large, real-world prostate cancer patient population on how patients live with, and manage, their disease. Every patient with cancer will face his or her own unique journey and we are committed to helping redefine that journey. We hope that these findings will help us improve outcomes for cancer patients in the future,” said Jane Griffiths, Company Group Chairman, Janssen European, Middle East and Africa (EMEA).

Among the abstracts selected for presentation is data from the Prostate Cancer Registry, the first and largest prospective study of European patients with metastatic castration-resistant prostate cancer (mCRPC).

Also in prostate cancer, a follow-up analysis from the COU-AA-302 study, investigating long-term safety of ZYTIGA® (abiraterone acetate) for the treatment of mCRPC, will be presented. In addition, the design of the TITAN and ATLAS trials will be presented; the trials will study the efficacy and safety profiles of apalutamide, a new generation androgen receptor inhibitor, in patients with newly-diagnosed mCRPC.

In bladder cancer, Phase 1 data will be presented around urothelial carcinoma (UC) examining the safety, efficacy and tolerability in patients treated with the pan-fibroblast growth factor receptor (FGFR) inhibitor erdafitinib.

Haematological malignancy data to be featured includes results from the Phase 3 CASTOR study, evaluating DARZALEX® (daratumumab) in combination with bortezomib and dexamethasone, compared to bortezomib and dexamethasone alone in patients with multiple myeloma who received one or more prior lines of therapy. This study has been published in the New England Journal of Medicine and formed the basis for recent submissions to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA), seeking to expand existing licenses for DARZALEX.1

The following Janssen abstracts have been accepted for presentation at the 2016 ESMO congress:

  • Haematological Malignancies, Proffered Paper Session, 9 th October, 11:00-12:00 CEST (Bern):
    • 11:00-11:15: 906O - Phase 3 randomised study of daratumumab, bortezomib and dexamethasone (DVd) vs bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR2
  • Poster Display, 9 th October, 13:00 – 14:00 CEST (Copenhagen, Hall E):
    • 13:00-14:00: 738P - Meta-analysis of randomized clinical trials in metastatic castration resistant prostate cancer: Comparison of hypertension, neurological and psychiatric adverse events on enzalutamide and abiraterone acetate plus prednisone treatment3
    • 13:00-14:00: 740P - Safety of long-term (LT) treatment (tmt) of chemotherapy (chemo)-naïve metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with abiraterone acetate plus prednisone (AA+ P) for ≥ 4 years (yrs)4
    • 13:00-14:00: 746P - The prostate cancer registry: Patient characteristics, treatments and preliminary outcomes from a large observational study of metastatic castration-resistant prostate cancer (mCRPC)5
    • 13:00-14:00: 769 Trial in Progress (TiP) - ATLAS: A phase 3 trial evaluating the efficacy of apalutamide (ARN-509) in patients with high-risk localized or locally advanced prostate cancer receiving primary radiation therapy6
    • 13:00-14:00: 771TiP - TITAN: A randomized, double-blind, placebo-controlled, phase 3 trial of apalutamide (ARN-509) plus androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC)7
    • 13:00-14:00: 789P - Pharmacokinetics (PK) of the pan-FGFR inhibitor erdafitinib in urothelial carcinoma8
    • 13:00-14:00: 845TiP - Ongoing phase 2 study of erdafitinib (JNJ-42756493), a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients (pts) with metastatic or unresectable urothelial carcinoma (M/UR UC) and FGFR gene alterations9
  • Genitourinary Tumours Non-Prostate, Poster Discussion Session, 9 th October, 16:30-17:30 CEST (Athens):
    • 17:10-17:30: 781PD - Safety and activity of the pan–fibroblast growth factor receptor (FGFR) inhibitor erdafitinib in phase 1 study patients with advanced urothelial carcinoma10
  • Poster Display, 10 th October, 13:00 – 14:00 CEST (Copenhagen, Hall E):
    • 13:00-14:00: 1161P - Utility of a targeted NGS oncology assay for circulating tumor DNA in a multi-histology clinical setting11

Please note that all abstracts accepted for presentation at the ESMO congress are subject to the organisers’ embargo policies.

-ENDS-

NOTES TO EDITORS

About the Janssen Pharmaceutical Companies

At the Janssen Pharmaceutical Companies of Johnson & Johnson, we are working to create a world without disease. Transforming lives by finding new and better ways to prevent, intercept, treat and cure disease inspires us. We bring together the best minds and pursue the most promising science. We are Janssen. We collaborate with the world for the health of everyone in it. Learn more at www.janssen.com/emea. Follow us at www.twitter.com/janssenEMEA.

References:

1 Palumbo A et al. Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2016;375(8):754-66.

2 Weisel K. Phase 3 randomised study of daratumumab, bortezomib and dexamethasone (DVd) vs bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR. Abstract #906O.

3 Ruiz Gracia, P. Meta-analysis of randomized clinical trials in metastatic castration resistant prostate cancer: Comparison of hypertension, neurological and psychiatric adverse events on enzalutamide and abiraterone acetate plus prednisone treatment. Abstract #738P. Available at: https://cslide.ctimeetingtech.com/library/esmo/browse/search/LXm#2z95v0T9.Last accessed September 2016.

4 Carles, J. Safety of long-term (LT) treatment (tmt) of chemotherapy (chemo)-naïve metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with abiraterone acetate plus prednisone (AA+ P) for ≥ 4 years (yrs). Abstract #740P. Available at: https://cslide.ctimeetingtech.com/library/esmo/browse/search/LXP#2z95v0Ko. Last accessed September 2016.

5 Chowdhury, S. The prostate cancer registry: Patient characteristics, treatments and preliminary outcomes from a large observational study of metastatic castration-resistant prostate cancer (mCRPC). Abstract #746P. Available at: https://cslide.ctimeetingtech.com/library/esmo/browse/search/LWu#2z95v0qo. Last accessed September 2016.

6 Bossi, A. ATLAS: A phase 3 trial evaluating the efficacy of apalutamide (ARN-509) in patients with high-risk localized or locally advanced prostate cancer receiving primary radiation therapy. Abstract #769TiP. Available at: https://cslide.ctimeetingtech.com/library/esmo/browse/search/LY6#2z95v0oF. Last accessed September 2016

7 Chi, K. TITAN: A randomized, double-blind, placebo-controlled, phase 3 trial of apalutamide (ARN-509) plus androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC). Abstract #771TiP. Available at: https://cslide.ctimeetingtech.com/library/esmo/browse/search/LYf#2z95v0yr. Last accessed September 2016.

8 Tabernero, J. Pharmacokinetics (PK) of the pan-FGFR inhibitor erdafitinib in urothelial carcinoma. Abstract #789P. Available at: https://cslide.ctimeetingtech.com/library/esmo/browse/search/Kws#2z95v0uv. Last accessed September 2016.

9 Siefker-Radtke, A. Ongoing phase 2 study of erdafitinib (JNJ-42756493), a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients (pts) with metastatic or unresectable urothelial carcinoma (M/UR UC) and FGFR gene alterations. Abstract #845TiP. Available at: https://cslide.ctimeetingtech.com/library/esmo/browse/search/LYJ#2z95v0wX. Last accessed September 2016.

10 Soria, J.C. Safety and activity of the pan–fibroblast growth factor receptor (FGFR) inhibitor erdafitinib in phase 1 study patients with advanced urothelial carcinoma. Abstract #781PD. Available at: https://cslide.ctimeetingtech.com/library/esmo/browse/search/LYX#2z94X0Jt. Last accessed September 2016.

11 Eerkes, T. Utility of a targeted NGS oncology assay for circulating tumor DNA in a multi-histology clinical setting. Abstract #1161P. Available at: https://cslide.ctimeetingtech.com/library/esmo/browse/search/LZj#2z95w0Yd. Last accessed September 2016.

Date of preparation: September 2016
Job number: PHEM/ONCS/0916/0002

Contact information

Media Enquiries:
Natalie Buhl
+353-85-7446696
or
Investor contacts:
Lesley Fishman
+1-732-524-3922
or
Joseph J. Wolk
+1-732-524-1142

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

AstraZeneca and Chi-Med’s Savolitinib Shows Encouraging Clinical Activity in 2nd-Line EGFR Mutation-positive Lung Cancer with MET-amplification16.10.2017 22:00Pressemelding

AstraZeneca and its partner Chi-Med today presented preliminary safety and clinical activity of savolitinib when given in combination with either Tagrisso (osimertinib) or Iressa (gefitinib) in two Phase Ib trials conducted in patients with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) with MET-amplification who had progressed following 1st-line treatment with an EGFR inhibitor.1,2 In both trials, the addition of savolitinib (600mg, once daily), an investigational selective inhibitor of c-MET (mesenchymal epithelial transition factor) receptor tyrosine kinase, to osimertinib (80mg, once daily) or gefitinib (250mg, once daily) demonstrated preliminary anti-tumour activity. The data were shared in two oral presentations at the International Association for the Study of Lung Cancer 18th World Conference on Lung Cancer (WCLC) in Yokohama, Japan, 15-18 Oc

Orlando Melbourne Int’l (MLB) Lands Largest FAA Grant in Its History16.10.2017 21:34Pressemelding

When Air Force One landed at Orlando Melbourne International Airport (MLB) in February, Airport Executive Director Greg Donovan took advantage of the opportunity and advised the president of the United States that his 747-200 just landed on a commercial runway officially rated ‘poor’ in aviation terms. That’s going to change, thanks to an $18,132,588 FAA grant announced by U.S. Secretary of Transportation Elaine Chao today. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171016006292/en/ Greg Donovan, A.A.E. (Photo: Business Wire) “We asked for, and received, tremendous support from the Florida congressional delegation,” said Jack L. Ryals, chairman of the Melbourne Airport Authority. “We are deeply grateful to Congressman Posey, Senator Nelson and Senator Rubio for their advocacy on this critic

Colombia Selects IDEMIA to Upgrade Its Identification and Civil Registry Platform16.10.2017 14:34Pressemelding

IDEMIA, the global leader in trusted identities for an increasingly digital world, has been selected by the National Civil Registry of Colombia (Registraduría Nacional del Estado Civil de Colombia – RNEC 1 ) to update the identification and civil registry platform. This platform is the trusted repository of citizens’ biometric and alphanumeric data and ensures the uniqueness of identities. IDEMIA (formerly known as OT-Morpho) has worked with the RNEC since the beginning of this project and has constantly supported the successive improvements of the solution. In 2017, when in need to strengthen the platform in order to offer new services to the government and to the population while maintaining a high level of security and satisfaction of the users, RNEC decided to pursue its partnership with IDEMIA. Through this new contract, IDEMIA will e

ATB Financial Goes-Live on Murex’s SaaS Solution16.10.2017 14:00Pressemelding

Sibos - Murex, a global leader in trading, risk management and processing solutions, is pleased to announce the successful launch of the MX.3 SaaS solution at ATB Financial. MUREX SaaS is a managed services offering for the MX.3 platform, encompassing infrastructure and application management. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171016005092/en/ ATB pursued this initiative in order to create a simple yet comprehensive foreign exchange experience for their customers. In addition to the customer benefit, ATB was also able to rationalize their IT landscape, broaden the scope of financial instruments they provide on their digital platform, and prepare for a large volume increase in their trading activities. Due to the strength of the solution’s risk management capabilities, extensive asset class coverage, and the ra

Leave a review on print24.com and win a VW up!16.10.2017 13:59Pressemelding

The online print shop UNITEDPRINT SE, owner of renowned brands including print24.com, is asking its customers for their opinions on the company’s products and services. In return for their views, customers will receive vouchers and be entered into a prize draw. The online print shop is offering one voucher for every review submitted across various portals. The vouchers – worth up to €25.00 and valid until 31 March 2018 – will be subject to a minimum order amount (product price inc. VAT, not including delivery) of €250.00 per voucher. All reviews received up to 31 December 2017 will be eligible, regardless of length and content. You can learn more about the review campaign at https://print24.com/rate/ But not only that, print24.com is also giving every reviewer the chance to win a brand-new VW up! Ali Jason Bazooband, Managing Director for Innovation/Marketing at print24.com,

Bentley Systems Announces Winners of 2017 Be Inspired Awards16.10.2017 13:52Pressemelding

The Year in Infrastructure 2017 Conference – Bentley Systems, Incorporated, a leading global provider of comprehensive software solutions for advancing infrastructure, has announced the winners of the 2017 Be Inspired Awards. The annual awards program honors the extraordinary work of Bentley users advancing the world’s infrastructure. At a ceremony and gala at their Year in Infrastructure 2017 Conference, Bentley acknowledged 17 Be Inspired Awards winners and six Special Recognition Awards winners. The Year in Infrastructure Conference is Bentley’s annual global gathering of leading professionals in the world of infrastructure design, construction, and operations. In addition to thought-provoking keynotes, technology demonstrations, industry forums, and panel discussions, the agenda included presentations by finalists in the Be Inspired Awards program, culminating in the selection of t

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom